tiprankstipranks

Rigel Pharmaceuticals resolves patent litigation related to Tavalisse

Rigel Pharmaceuticals resolves patent litigation related to Tavalisse

Rigel Pharmaceuticals (RIGL) announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA resolving patent litigation related to Rigel’s product Tavalisse. The litigation resulted from submission by Annora of an Abbreviated New Drug Application to the U.S. FDA seeking approval to market a generic version of Tavalisse in the United States. Under the terms of the settlement agreement, Annora will have a license to sell its generic product in Q2 2032 or earlier under certain circumstances. In accordance with the agreement, the parties terminated all ongoing litigation between Rigel and Annora regarding Tavalisse patents pending in New Jersey.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue